Ramírez-Melo Jorge Luis, Moreira Daniel C, Orozco-Alvarado Ana Luisa, Sánchez-Zubieta Fernando, Navarro-Martín Del Campo Regina M
Pediatric Oncology and Hematology Service, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Mexico.
Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, United States.
Front Oncol. 2024 Feb 13;14:1329729. doi: 10.3389/fonc.2024.1329729. eCollection 2024.
Patients with optic pathway gliomas (OPG) have good survival rates although their long-term quality of life can be affected by the tumor or treatment-related morbidity. This retrospective study sought to describe the clinical presentation and outcomes of children with OPG at a tertiary center in Mexico.
Consecutive patients <18 years-of-age with newly diagnosed OPG between January 2002 and December 2020 at the Hospital Civil de Guadalajara Dr. Juan I. Menchaca in Guadalajara, Mexico were included.
Thirty patients were identified with a median age of six years. The most frequent clinical manifestations were loss of visual acuity (40%) and headaches (23%). Neurofibromatosis-1 was found in 23.3% of the patients. Surgery, either biopsy or resection, was done in 20 of 30 patients. Two patients died shortly after initial surgery. The 5-year event-free survival (EFS) was 79.3% ± 10.8% and the 5-year overall survival was 89.5% ± 6.9%. Lower EFS was associated with age less than 3 years, intracranial hypertension at presentation, and diencephalic syndrome. Patients who received surgery as first-line treatment had a 3.1 times greater risk of achieving a performance score of less than 90 points at 6 months after diagnosis (p=0.006). Of 10 patients with vision testing, 5 had improvement in visual acuity, 4 had no changes, and one patient showed worsening.
Our data suggests that favorable outcomes can be achieved with OPG in low- and middle-income countries, although a high rate of surgical complications was described leading to a lower overall survival. These data can be used prospectively to optimize treatment at this institute and other middle-income countries through a comprehensive, multidisciplinary approach.
视神经通路胶质瘤(OPG)患者的生存率较高,但其长期生活质量可能会受到肿瘤或治疗相关并发症的影响。这项回顾性研究旨在描述墨西哥一家三级中心儿童OPG的临床表现和治疗结果。
纳入2002年1月至2020年12月期间在墨西哥瓜达拉哈拉市胡安·I·门查卡公民医院新诊断为OPG的18岁以下连续患者。
共确定30例患者,中位年龄为6岁。最常见的临床表现是视力丧失(40%)和头痛(23%)。23.3%的患者患有神经纤维瘤病1型。30例患者中有20例接受了手术,包括活检或切除术。两名患者在初次手术后不久死亡。5年无事件生存率(EFS)为79.3%±10.8%,5年总生存率为89.5%±6.9%。较低的EFS与年龄小于3岁、就诊时颅内高压和间脑综合征有关。接受手术作为一线治疗的患者在诊断后6个月时获得低于90分的性能评分的风险高3.1倍(p=0.006)。在10例进行视力测试的患者中,5例视力有所改善,4例无变化,1例视力恶化。
我们的数据表明,在低收入和中等收入国家,OPG可以取得良好的治疗效果,尽管手术并发症发生率较高,导致总生存率较低。这些数据可前瞻性地用于通过全面、多学科方法优化该机构和其他中等收入国家的治疗。